Literature DB >> 24229761

Monitoring treatment and managing adherence in schizophrenia.

Stephen R Marder1.   

Abstract

The majority of patients with schizophrenia will be nonadherent at some point during their treatment, which is why clinicians must assess adherence at each visit and promptly address any barriers. Treatment adherence can be negatively impacted by substance use, cognitive impairment, complex treatment regimens, and antipsychotic-induced adverse effects. Clinicians must monitor these risk factors, particularly metabolic, neurologic, and other side effects, not only to improve adherence but also to protect patients from dangerous health conditions. Interventions that can address some barriers to treatment adherence include adjusting medications as necessary, implementing lifestyle changes, using long-acting injectable antipsychotics, educating patients and their families, and implementing psychosocial therapy. With the appropriate interventions and support, patients with schizophrenia can maintain their treatment regimens and avoid relapse. © Copyright 2013 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24229761     DOI: 10.4088/JCP.12117tx2c

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

Review 1.  The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.

Authors:  Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

2.  Magnitude, Nature, and Risk Factors of Adverse Drug Reactions Associated with First Generation Antipsychotics in Outpatients with Schizophrenia: A Cross-Sectional Study.

Authors:  Merhawi Bahta; Tzeggai Berhe; Mulugeta Russom; Eyasu H Tesfamariam; Azieb Ogbaghebriel
Journal:  Integr Pharm Res Pract       Date:  2020-10-14

3.  Check the effects: systematic assessment of antipsychotic side-effects in an inpatient cohort.

Authors:  Caroline Hynes; Stephen McWilliams; Mark Clarke; Ita Fitzgerald; Larkin Feeney; Mark Taylor; Fiona Boland; Dolores Keating
Journal:  Ther Adv Psychopharmacol       Date:  2020-09-25

4.  Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?

Authors:  Cinzia Niolu; Emanuela Bianciardi; Giorgio Di Lorenzo; Claudia Marchetta; Ylenia Barone; Nicoletta Sterbini; Michele Ribolsi; Giorgio Reggiardo; Alberto Siracusano
Journal:  Ther Adv Psychopharmacol       Date:  2015-10

5.  Measuring adherence to medication in schizophrenia: the relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics.

Authors:  Nursen Yalcin-Siedentopf; Fabienne Wartelsteiner; Alexandra Kaufmann; Falko Biedermann; Monika Edlinger; Georg Kemmler; Maria A Rettenbacher; Christian G Widschwendter; Gerald Zernig; W Wolfgang Fleischhacker; Alex Hofer
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-07       Impact factor: 5.176

6.  Do patterns of mental healthcare predict treatment failure in young people with schizophrenia? Evidence from an Italian population-based cohort study.

Authors:  Giovanni Corrao; Davide Soranna; Luca Merlino; Emiliano Monzani; Caterina Viganò; Antonio Lora
Journal:  BMJ Open       Date:  2015-06-03       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.